Every 424B that SAB Biotherapeutics, Inc. (SABS) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow SABS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SABS filings page.
SAB Biotherapeutics, Inc. (SABS) filed a prospectus supplement updating the selling stockholder table for an existing resale registration covering up to 250,000,000 shares of Common Stock. These shares are issuable upon conversion of Series B Convertible Preferred Stock and Series B Preferred Stock purchase warrants held by selling stockholders.
The registered shares include 100,000,000 shares issuable upon conversion of Series B Preferred Stock, 100,000,000 shares issuable upon conversion of Enrollment Date Warrant Shares, and 50,000,000 shares issuable upon conversion of Release Date Warrant Shares. The supplement states it is filed solely to reflect a transfer of securities between a selling stockholder and its affiliate, and allows these holders to resell their shares from time to time, subject to 4.99% or 9.99% beneficial ownership blockers in many cases. SABS common stock trades on the Nasdaq Capital Market under the symbol SABS, with a reported closing price of $3.79 per share on August 18, 2026.
SAB Biotherapeutics is offering 19,324,677 shares of common stock and, in lieu of shares to certain investors, pre-funded warrants to purchase up to 2,753,246 shares of common stock at a public offering price of $3.85 per share ($3.8499 per pre-funded warrant). The offering includes a 30-day underwriter option to purchase an additional 3,311,688 shares. Delivery is expected on or about March 19, 2026.
The company estimates net proceeds to the issuer of approximately $69.7 million (about $81.7 million if the option is exercised in full) and intends to use proceeds to fund continued development and clinical trials of its lead candidate, SAB-142, related manufacturing, regulatory and operational activities, and for working capital.
SAB Biotherapeutics is offering shares of common stock and pre-funded warrants in a shelf-based public offering. The prospectus supplement describes an offering of common stock and, in lieu of shares, pre-funded warrants exercisable for one share at an exercise price of $0.0001 per share. The company’s common stock trades on The Nasdaq Capital Market under the symbol SABS, and it reported 47,609,899 shares outstanding as of December 31, 2025. The prospectus references proceeds, underwriting arrangements, a 30-day option for additional shares, and customary underwriting terms; specific offering amounts and pricing are presented only in completed prospectus pages. The supplement also summarizes business and clinical developments: SAB-142 is the lead clinical candidate, the company received an IND clearance in May 2024, announced positive Phase 1 topline data across multiple dates including additional Phase 1 data on March 10, 2026, and is advancing SAB-142 into a Phase 2b SAFEGUARD study after a Type B meeting with the FDA on May 29, 2025.
SAB Biotherapeutics filed a prospectus supplement for a resale registration covering up to 250,000,000 shares of common stock to be offered by selling stockholders. The Resale Shares consist of common stock issuable upon conversion of Series B Convertible Preferred Stock and upon exercise of related Series B preferred stock purchase warrants that yield additional Series B shares for conversion.
This supplement states it is solely to update a footnote in the selling stockholders table. The selling stockholder list includes large allocations, including SESSA CAPITAL (MASTER) L.P. 57,125,000 and RA Capital Healthcare Fund, L.P. 42,850,000. Several holders are subject to beneficial ownership limits of 4.99% or 9.99% that cap conversions. The company’s common stock trades on Nasdaq as SABS; on November 5, 2025, the closing price was $3.18. The Series B Preferred Stock is not listed and is not intended to be listed.